Pharsight

Bydureon patents expiration

BYDUREON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 3 months from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5424286 ASTRAZENECA AB Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Dec, 2016

(7 years ago)

US6858576 ASTRAZENECA AB Methods for regulating gastrointestinal motility
Jan, 2017

(7 years ago)

US7741269 ASTRAZENECA AB Exendins and exendin agonists for weight reduction and obesity
Jan, 2018

(6 years ago)

US6956026 ASTRAZENECA AB Use of exendins for the reduction of food intake
Jan, 2018

(6 years ago)

US6872700 ASTRAZENECA AB Methods for glucagon suppression
Jan, 2020

(4 years ago)

US6495164 ASTRAZENECA AB Preparation of injectable suspensions having improved injectability
May, 2020

(4 years ago)

US6667061 ASTRAZENECA AB Preparation of injectable suspensions having improved injectability
May, 2020

(4 years ago)

US6479065 ASTRAZENECA AB Process for the preparation of polymer-based sustained release compositions
Aug, 2020

(3 years ago)

US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US7223440 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Aug, 2021

(2 years ago)

US7223440

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Mar, 2022

(2 years ago)

US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Oct, 2022

(1 year, 8 months ago)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Apr, 2023

(1 year, 2 months ago)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(2 months ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(2 months ago)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(3 months from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(3 months from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(9 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(9 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(9 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 14 days from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 3 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 3 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 3 months from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 6 months from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 9 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

US8216180 ASTRAZENECA AB Administering apparatus with functional drive element
Jan, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Mar, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(4 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

Bydureon is owned by Astrazeneca Ab.

Bydureon contains Exenatide Synthetic.

Bydureon has a total of 46 drug patents out of which 17 drug patents have expired.

Expired drug patents of Bydureon are:

  • US5424286
  • US6858576
  • US7741269
  • US6956026
  • US6872700
  • US6495164
  • US6667061
  • US6479065
  • US6936590
  • US9198925
  • US7223440
  • US7223440*PED
  • US6824822
  • US6824822*PED
  • US7563871
  • US9238076
  • US6414126

Bydureon was authorised for market use on 27 January, 2012.

Bydureon is available in for suspension, extended release;subcutaneous dosage forms.

Bydureon can be used as treating type 2 diabetes mellitus with exenatide by stimulating insulin release, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin, as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea, improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise, treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone, reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4, reductions in body weight are observed with exenatide, lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4, reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4, as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication.

The generics of Bydureon are possible to be released after 26 May, 2030.

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4; Reductions in bo...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents